Vital Therapies has secured $22.5 million in a round of financing from 15 investors. The San Diego company will use the money to further develop its ELAD bioartificial liver, which could provide continuous liver support for patients being treated for hepatitis B, alcohol hepatitis and acute organ failure.
Calif. company developing bioartificial liver gets $22.5M boost
SmartBrief Job Listings for Health Care
|Compliance and Ethics Director||
Sysmex America, Inc.
|Director, Site Quality Management||
|Palm Springs, CA|
|Compliance Officer-Medical Products||
W. L. Gore